|
Sign In to gain access to subscriptions and/or personal tools.
|
Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment
Wolfgang C. Winkelmayer, MD, ScD
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts
Milton C. Weinstein, PhD
Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts
Murray A. Mittleman, MD, DrPH
Department of Epidemiology, Harvard School of Public Health, and the Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Robert J. Glynn, PhD, ScD
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts
Joseph S. Pliskin, PhD
Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, Department of Health Policy and Management, Ben-Gurion University of the Negev, Beer Sheba, Israel
This article synthesizes the evidence on the cost-effectiveness of renal replacement therapy and discusses the findings in light of the frequent practice of using the cost-effectiveness of hemodialysis as a benchmark of societal willingness to pay. The authors conducted a meta-analytic review of the medical and economic literature for economic evaluations of hemodialysis, peritoneal dialysis, and kidney transplantation. Cost-effectiveness ratios were translated into 2000 U.S. dollars per life-year (LY) saved. Thirteen studies published between 1968 and 1998 provided such information. The cost-effectiveness of center hemodialysis remained within a narrow range of $55,000 to $80,000/LY in most studies despite considerable variation in methodology and imputed costs. The cost-effectiveness of home hemodialysis was found to be between $33,000 and $50,000/LY. Kidney transplantation, however, has become more cost-effective over time, approaching $10,000/LY. Estimates of the cost per life-year gained from hemodialysis have been remarkably stable over the past 3 decades, after adjusting for price levels. Uses of the cost-effectiveness ratio of $55,000/LY for center hemodialysis as a lower boundary of society’s willingness to pay for an additional life-year can be supported under certain assumptions.
Key Words: cost-effectiveness analysis • dialysis • kidney transplantation • meta-analysis
Medical Decision Making, Vol. 22, No. 5,
417-430 (2002)
DOI: 10.1177/027298902236927
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. J. Kim, J. Ortendahl, and S. J. Goldie
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Ann Intern Med,
October 20, 2009;
151(8):
538 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Greenblatt, C. Hur, A. B. Knudsen, J. A. Evans, D. C. Chung, and G. S. Gazelle
Cost-Effectiveness of Prophylactic Surgery for Duodenal Cancer in Familial Adenomatous Polyposis
Cancer Epidemiol. Biomarkers Prev.,
October 1, 2009;
18(10):
2677 - 2684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Delea, O. Sofrygin, J. L. Palmer, H. Lau, V. C. Munk, J. Sung, A. Charney, H.-H. Parving, and S. D. Sullivan
Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
J. Am. Soc. Nephrol.,
October 1, 2009;
20(10):
2205 - 2213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Patrick, J. Avorn, and N. K. Choudhry
Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
Circ Cardiovasc Qual Outcomes,
September 1, 2009;
2(5):
429 - 436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Chailimpamontree, S. Dmitrienko, G. Li, R. Balshaw, A. Magil, R. J. Shapiro, D. Landsberg, J. Gill, P. A. Keown, and and the Genome Canada Biomarkers in Transplantatio
Probability, Predictors, and Prognosis of Posttransplantation Glomerulonephritis
J. Am. Soc. Nephrol.,
April 1, 2009;
20(4):
843 - 851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Rogowski
The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study
Med Decis Making,
March 1, 2009;
29(2):
224 - 238.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Raftery
Should NICE's threshold range for cost per QALY be raised? No
BMJ,
January 26, 2009;
338(jan26_2):
b185 - b185.
[Full Text]
|
|
|
|
|
|
|
A.E. Courtney, P.T. McNamee, and A.P. Maxwell
The evolution of renal transplantation in clinical practice: for better, for worse?
QJM,
December 1, 2008;
101(12):
967 - 978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Bayoumi MD MSc and G. S. Zaric PhD
The cost-effectiveness of Vancouver's supervised injection facility
Can. Med. Assoc. J.,
November 18, 2008;
179(11):
1143 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Pandharipande, M. G. Harisinghani, E. M. Ozanne, M. C. Specht, C. Hur, J. M. Lee, and G. S. Gazelle
Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis
Am. J. Roentgenol.,
November 1, 2008;
191(5):
1308 - 1319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Just, F. Th. de Charro, E. A. Tschosik, L. L. Noe, S. K. Bhattacharyya, and M. C. Riella
Reimbursement and economic factors influencing dialysis modality choice around the world
Nephrol. Dial. Transplant.,
July 1, 2008;
23(7):
2365 - 2373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Pandharipande, D. A. Gervais, P. R. Mueller, C. Hur, and G. S. Gazelle
Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis
Radiology,
July 1, 2008;
248(1):
169 - 178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Gill, S. Hussain, C. Rose, S. Hariharan, and M. Tonelli
Access to Kidney Transplantation among Patients Insured by the United States Department of Veterans Affairs
J. Am. Soc. Nephrol.,
September 1, 2007;
18(9):
2592 - 2599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Dahm, M. Weber, B. Muller, F. G. Pradel, G. F. Laube, T. J. Neuhaus, C. Cao, R. P. Wuthrich, G. T. Thiel, and P.-A. Clavien
Open and laparoscopic living donor nephrectomy in Switzerland: a retrospective assessment of clinical outcomes and the motivation to donate
Nephrol. Dial. Transplant.,
September 1, 2006;
21(9):
2563 - 2568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Daoud, K. G Amin, K. Mohan, and A R. Ahmed
Cost of Intravenous Immunoglobulin Therapy Versus Conventional Immunosuppressive Therapy in Patients with Mucous Membrane Pemphigoid: A Preliminary Study
Ann. Pharmacother.,
December 1, 2005;
39(12):
2003 - 2008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Neumann, A. B. Rosen, and M. C. Weinstein
Medicare and Cost-Effectiveness Analysis
N. Engl. J. Med.,
October 6, 2005;
353(14):
1516 - 1522.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Custer, M. P. Busch, A. A. Marfin, and L. R. Petersen
The Cost-Effectiveness of Screening the U.S. Blood Supply for West Nile Virus
Ann Intern Med,
October 4, 2005;
143(7):
486 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Norum, T. Risberg, and J. A. Olsen
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
Ann. Onc.,
June 1, 2005;
16(6):
909 - 914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Lee, C. LeBaron, T. V. Murphy, S. Lett, S. Schauer, and T. A. Lieu
Pertussis in Adolescents and Adults: Should We Vaccinate?
Pediatrics,
June 1, 2005;
115(6):
1675 - 1684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Beinfeld, E. Wittenberg, and G. S. Gazelle
Cost-effectiveness of Whole-Body CT Screening
Radiology,
February 1, 2005;
234(2):
415 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hur, L. S Simon, and G S. Gazelle
Analysis of Aspirin-Associated Risks in Healthy Individuals
Ann. Pharmacother.,
January 1, 2005;
39(1):
51 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C. Winkelmayer, R. Kramar, G. C. Curhan, A. Chandraker, G. Endler, M. Fodinger, W. H. Horl, and G. Sunder-Plassmann
Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients: A Prospective Study
J. Am. Soc. Nephrol.,
January 1, 2005;
16(1):
255 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Avorn and W. C. Winkelmayer
Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism
Circulation,
December 14, 2004;
110(24_suppl_1):
IV-25 - IV-32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Ozanne and L. J. Esserman
Evaluation of Breast Cancer Risk Assessment Techniques: A Cost-effectiveness Analysis
Cancer Epidemiol. Biomarkers Prev.,
December 1, 2004;
13(12):
2043 - 2052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N J Shaheen, J M Inadomi, B F Overholt, and P Sharma
What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis
Gut,
December 1, 2004;
53(12):
1736 - 1744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Cohen, S. A. Murphy, D. S. Baim, T. A. Lavelle, R. H. Berezin, D. E. Cutlip, K. K.L. Ho, R. E. Kuntz, and the SAFER Trial Investigators
Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: Results from the SAFER trial
J. Am. Coll. Cardiol.,
November 2, 2004;
44(9):
1801 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fabrizii, W. C. Winkelmayer, R. Klauser, J. Kletzmayr, M. D. Saemann, R. Steininger, R. Kramar, W. H. Horl, and J. Kovarik
Patient and Graft Survival in Older Kidney Transplant Recipients: Does Age Matter?
J. Am. Soc. Nephrol.,
April 1, 2004;
15(4):
1052 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hur, N. S. Nishioka, and G. S. Gazelle
Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus
J Natl Cancer Inst,
February 18, 2004;
96(4):
316 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K C. Kent, R. M Zwolak, M. R Jaff, S. T Hollenbeck, R. W Thompson, M. L Schermerhorn, G. A Sicard, T. S Riles, and J. L Cronenwett
Screening for abdominal aortic aneurysms - a consensus statement
Vascular Medicine,
February 1, 2004;
9(1):
87 - 89.
[PDF]
|
|
|
|
|
|
|
A. D. Cohen and N. E. Kemeny
An Update on Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer
Oncologist,
December 1, 2003;
8(6):
553 - 566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Stahl, K. L. Furie, S. Gleason, and G. S. Gazelle
Stroke: Effect of Implementing an Evaluation and Treatment Protocol Compliant with NINDS Recommendations
Radiology,
September 1, 2003;
228(3):
659 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Kulasingam and E. R. Myers
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
JAMA,
August 13, 2003;
290(6):
781 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
